23andMe and its customers’ genetic data bought by a pharmaceutical org

The bankrupt genetic testing company 23andMe has been scooped up by drug producer Regeneron Pharmaceuticals for $256 million dollars. But why would a pharmaceutical company like Regeneron buy a bankrupt genetics testing company like 23andMe for such a large amount of money? Well, Regeneron is a...